Novo Nordisk A/s Stock News

Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk.

Novo Nordisk A/S (NYSE: NVO ) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna''s closing price on November 17, 2021. "The acquisition of Dicerna accelerates Novo Nordisk''s research within RNAi Full story available on Benzinga.com

Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.

Qurates most recent research report on Catheters, Needles, And Cannulas was performed by extremely qualified research professionals and business experts in order to provide an in-depth assessment on the market. The study on Catheters, Needles, And Cannulas is extensive and

https://www.investing.com/news/economy/denmarks-novo-nordisk-to-buy-dicerna-pharma-for-33-billion-2683932

Novo Nordisk said it''s buying Dicerna Pharmaceuticals for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28. Novo Nordisk already had a research collaboration with Dicerna, and said the deal is part of a strategy of using a broad range of technology platforms applicable across all Novo Nordisk''s therapeutic focus areas. The existing collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets. Novo Nordisk said the deal will lead to an increase in research and development costs, with an estimated negative impact on operating profit growth in 2022 of around 3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk. The post DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Phar

Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% t

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA)  announced it entered into a definitive agreement with Novo Nordisk A/S (NYSE: NVO) under which Novo Nordisk will acquire Dicerna. This is why.

Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.

Hana Financial Group has landed a $210.7 million debt package to refinance Novo Nordisks North American headquarters in New Jersey.

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Smart Insulin Pens Market The smart insulin pens market was valued at USD 73.8 million in 2019 and is expected to grow with a CAGR of 10.8%. Smart insulin pens are smart devices that are used externally to inject insulin to patients with